BridgeMD
New treatment option for COVID-19, Long Haul
Official title Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.
ClinicalTrials.gov ID: NCT06441955
What this study is testing
What is Ritonavir-Boosted Nirmatrelvir (Paxlovid)?
Ritonavir-Boosted Nirmatrelvir (Paxlovid) is an investigational medicine, being studied as a potential treatment for covid-19, long haul.
Also referred to as Phramacotherapies.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms. The symptoms of long COVID can include extreme tiredness (fatigue), shortness of breath, memory and concentration issues (brain fog), heart palpitations, dizziness, joint pain, muscle aches, cough, headaches, anxiety, and depression.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65. Healthy volunteers may be eligible.
You may be able to join if
- Inclusion of Men, Women, and Minorities
- Participants must be at least 18 years old.
- Participants must have a positive COVID-19 diagnosis or clinical diagnosis of COVID-19
- Participants must have experienced persistent symptoms after recovering from the acute phase of the illness.
- Participants must be willing to provide informed consent to participate in the study.
You likely can't join if
- \>18 years of age
- Medical History of Myocarditis
- Medical History of Pericarditis
- Medical History of Severe renal impairment (eGFR \<30 mL/min).
See the full eligibility criteria
- Inclusion of Men, Women, and Minorities
- Participants must be at least 18 years old.
- Participants must have a positive COVID-19 diagnosis or clinical diagnosis of COVID-19
- Participants must have experienced persistent symptoms after recovering from the acute phase of the illness.
- Participants must be willing to provide informed consent to participate in the study.
- Participants must be able to communicate effectively in English or have a translator available.
- Participants must be able to attend follow-up appointments as required by the study protocol.
- Participants must not have any medical conditions or take any medications that could interfere with the study results.
- \>18 years of age
- Medical History of Myocarditis
- Medical History of Pericarditis
- Medical History of Severe renal impairment (eGFR \<30 mL/min).
The study team makes the final eligibility decision.
Where it's taking place
- Bethesda, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bethesda, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.